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CXCR4 antagonistC-X-C motif chemokine 12/C-X-C chemokine receptor type 4 (CXCL12/CXCR4) signaling is involved in
ontogenesis, hematopoiesis, immune function and cancer. Recently, the orphan chemokine CXCL14
was reported to inhibit CXCL12-induced chemotaxis – probably by allosteric modulation of CXCR4.
We thus examined the effects of CXCL14 on CXCR4 regulation and function using CXCR4-transfected
human embryonic kidney (HEK293) cells and Jurkat T cells. CXCL14 did not affect dose–response
proﬁles of CXCL12-induced CXCR4 phosphorylation, G protein-mediated calcium mobilization,
dynamic mass redistribution, kinetics of extracellular signal-regulated kinase 1 (ERK1) and ERK2
phosphorylation or CXCR4 internalization. Hence, essential CXCL12-operated functions of CXCR4
are insensitive to CXCL14, suggesting that interactions of CXCL12 and CXCL14 pathways depend
on a yet to be identiﬁed CXCL14 receptor.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
CXC chemokine ligand (CXCL)12, also known as stromal cell-
derived factor (SDF)-1, is the ﬁrst chemokine that was shown to
be essential for cell migration and homing processes during devel-
opment. These include formation of the hematopoietic, cardiovas-
cular, nervous and reproductive systems. In the adult organism,
CXCL12 regulates stem and immune cell trafﬁcking in the bone
marrow, lymphatic tissues and brain [1–3]. CXCL12 mediates these
effects through chemokine receptors CXCR4 and CXCR7. CXCL12
receptors are targets in HIV infection, cancer, inﬂammation and
cell-based regenerative therapy. The CXCR4 antagonist AMD3100
(Plerixafor) is approved to liberate hematopoietic stem cells in
tumor patients and there is considerable interest in new CXCR4
antagonists and allosteric modulators of CXCL12/CXCR4 signaling
[4–12].
While most chemokine receptors recognize several endogenous
ligands, CXCR4 binds CXCL12 but no other chemokines [11]. This
widely accepted view has recently been challenged by the report
of a high afﬁnity interaction (Kd 14.7 nM) of CXCL14 (BRAK) and
CXCR4 [13]. The interaction is thought to be mediated by the
CXCL14 C terminus [14], which distinguishes it from the CXCL12/CXCR4 interaction that is mediated by the CXCL12 N terminus
[15]. The authors reported further that CXCL14 reduced CXCL12-
induced migration of leukemia-derived cells and hematopoietic
progenitors in a transwell assay and that CXCL14/CXCR4 complex
formation was not inhibited by CXCL12. These ﬁndings suggest
that CXCL14 might function as an allosteric inhibitor of the
CXCL12/CXCR4 pathway.
CXCL14 is widely expressed in many tissues but – apart from
the reported CXCL14/CXCR4 interaction – CXCL14 receptors are
still unknown [11,16]. CXCL14 modulates immune cell trafﬁcking,
exerts tumor-supportive or tumor-suppressive functions and regu-
lates glucose metabolism as well as feeding-related neuronal cir-
cuits [17]. Given this unique functional proﬁle and the existence
of a selective high afﬁnity CXCL14 binding site in immature mono-
cyte-derived dendritic cells [18], existence of a distinct CXCL14
receptor is conceivable.
CXCL12 and CXCL14 transcripts are co-distributed in many tis-
sues [16,19], suggesting that functional interactions of CXCL12 and
CXCL14 pathways are possible. In fact, both chemokines are
strongly expressed in neurons and exert opposing effects on
GABAergic transmission in the dentate gyrus [20]. Such interaction
may occur downstream of CXCR4 and the putative CXCL14 recep-
tor or at the receptor level. Given the recent reports that CXCL14
functions as an allosteric modulator of CXCR4 [13,14], we exam-
ined if CXCL14 inﬂuences CXCL12-induced activation and signaling
of CXCR4.
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2.1. Compounds
CXCL12 and CXCL14 (PeproTech, Hamburg, Germany),
AMD3100 (Sigma–Aldrich), AMD3465 (Tocris).
2.2. Cell culture
HEK293 cells (DSMZ, Braunschweig, Germany) were cultivated
in DMEM (PAA Laboratories, Pasching, Austria) supplemented with
10% deﬁned fetal bovine serum (FBS GOLD, PAA), 2 mM L-gluta-
mine and 100 units/ml penicillin/streptomycin (PAA). JetPEI (PEQ-
LAB Biotechnology, Erlangen, Germany) was used for transient and
stable transfections with human CXCR4 carrying an N-terminal
hemagglutinin (HA)-epitope tag (#CXCR40TN00, cDNA Resource
Center, MO). Stable transfectants were selected in the presence of
increasing concentrations of G418 (0.1–0.5 mg/ml). After 14 days,
aliquots of several resistant polyclones were tested for stable
transfection by immunostaining of the HA-epitope. A polyclonal
population with >75% HA-positive stable transfectants was
selected and maintained in 0.5 mg/ml G418 for further experi-
ments. Jurkat T cells were cultivated as described [24].
2.3. Measurement of dynamic mass redistribution (DMR) and calcium
mobilization
For label-free measurement of DMR [21,22], stable transfec-
tants were seeded at a density of 50000 cells per well in poly-L-
lysine-coated 96 well EnSpire microplates (PerkinElmer, Rodgau,
Germany) and grown for 24 h to achieve conﬂuent cell layers. Cells
were washed four times with assay buffer (1 Hank’s balanced salt
solution containing 20 mM HEPES, pH7.1), supplemented with
80 ll assay buffer and incubated for 1 h at 25 C in the EnSpire
Multimode Plate-Reader to achieve temperature equilibration. In
pre-stimulation experiments, CXCL14 or CXCR4 antagonists were
added 10 min before starting the measurements. After baseline
recording (300 s) to deﬁne the zero level, CXCL12, CXCL14, or vehi-
cle (assay buffer) were added and DMR was monitored.
For measurement of [Ca2+]i, the FlexStation3-Microplate-Reader
and calcium assay kit IV (Molecular Devices, Sunnyvale, CA) were
used. HEK293 cells were co-transfected with CXCR4 and the qi5
chimeric G protein that was engineered to link Gi/o-coupled recep-
tors to Ca2+ mobilization [23–25]). 75000 cells were seeded per
well in 96 well plates. Measurements were performed on the fol-
lowing day as described previously [24,25].
2.4. Erk1,2-phosphorylation and CXCR4-phosphorylation assays
For the Erk1,2 assay, 300000 stably transfected cells were pla-
ted per well in 24 well plates, grown overnight and supplemented
with assay buffer (DMEM containing 0.1% BSA) for 1 h. Chemokines
and CXCR4 antagonists were dissolved in assay buffer and added as
explained in Section 3. Plates were cooled to 0 C to stop stimula-
tion. Cells were lysed immediately in 80 C SDS sample buffer.
Lysates were sonicated for 90 s and incubated for 5 min at 95 C.
Lysates were subjected to SDS polyacrylamide gel electrophoresis
and electroblotted onto PVDF membrane (Carl Roth, Karlsruhe,
Germany). Blots were reacted simultaneously with anti-pErk1,2
(#4347, Cell Signaling Technology, Danvers) and anti-Akt (#07-
416, Merck Millipore) as loading control. Anti-rabbit-HRP (Santa
Cruz Biotechnology, Dallas), HRP detection kit (Thermoscientiﬁc,
Rockford) and the Fusion FX7 imaging station were used for detec-
tion. The ratio of the pErk1,2 and Akt signals of each sample was
normalized to the average pErk1,2/Akt ratio of the 50 nM CXCL12group before normalized pErk1,2/Akt ratios of repeat experiments
were averaged.
To examine CXCR4 phosphorylation in HEK293 cells, HA-CXCR4
was immunoprecipitated from stable transfectants using anti-HA
beads (Pierce). Receptors were eluted using SDS sample buffer
and analyzed by Western blot. CXCR4 phosphorylation in Jurkat
T cells was examined in immunoblotted wheat germ lectin aga-
rose-puriﬁed lysates as described [25]. Antibodies used for detec-
tion have been described recently [25,26].
2.5. Immunocytochemistry and ELISA
For immunocytochemistry, 250000 stable transfectants were
seeded on poly-D-lysine-coated coverslips in multi-well plates
and treated on the following day with chemokines and AMD3100
as described in Section 3. The cells were washed, ﬁxed with Zam-
boni’s ﬁxative, permeabilized (0.1% Triton X-100 in 15% normal
goat serum/PBS) and reacted with anti-HA [24] and Cy3-coupled
anti-rabbit antibodies (1: 400, Jackson ImmunoResearch Laborato-
ries). Confocal images were captured with a LSM 510 Meta (Carl
Zeiss, Jena, Germany).
For ELISA, 100000 stable transfectants were grown overnight in
48-well plates and treated on the following day as described in
Section 3. Cells were acid-washed (100 mM sodium citrate,
90 mM NaCl, pH 4.5), transferred to 4 C, labeled for 20 min with
anti-HA, ﬁxed and reacted with anti-rabbit peroxidase antibody
(1: 2000, 90 min RT, Santa Cruz Biotechnology Inc.). 1-Step™ Ultra
TMB-ELISA-reagent (Thermo Scientiﬁc) was used for detection.
After 5 min, 80 ll of the supernatant were collected and the color
reaction was terminated by adding 80 ll 2 M sulfuric acid. The
color intensity was measured using FlexStation3.
2.6. Statistics
Statistical tests were calculated using GraphPad Prism 4.0 soft-
ware. Levels of signiﬁcance of 0.05, 0.01 and 0.001 were indicated
by 1–3 symbols.
3. Results and discussion
3.1. CXCL14 does not inﬂuence CXCL12-induced CXCR4
phosphorylation
The conformational change of agonist-activated G protein-cou-
pled receptors (GPCRs) is recognized by heterotrimeric G proteins
and GPCR kinases (GRKs). The GPCR/GRK interaction results in
phosphorylation of activated receptors and desensitization of G
protein-mediated signaling [27]. It was recently established that
CXCL12 stimulation causes rapid phosphorylation of CXCR4 at ser-
ine residues 346 and 347 (S346,347) by GRKs2,3 [25,26,28–30]. We
reasoned that, if CXCL14 functioned as an allosteric modulator of
the CXCL12/CXCR4 pathway, it would shift the dose–response pro-
ﬁle of CXCL12-induced S346,347 phosphorylation. To test this, we
used HEK293 cells stably expressing HA-tagged human CXCR4. The
cells were pre-incubated for 10 min with 100 nM CXCL14 or vehi-
cle and then stimulated for 10 min with 0.2–66 nM CXCL12. Phos-
pho-selective anti-pS346,347 (Fig. 1A) and anti-HA antibodies
were used to detect phosphorylated and total CXCR4, respectively.
In addition, we applied the phospho-sensitive antibody UMB-2
(Fig. 1A), which recognizes only the non-phosphorylated C termi-
nus of non-activated CXCR4 (residues 341–352) [25]. A representa-
tive experiment is shown in Fig. 1B. S346,347-phosphorylation
increased signiﬁcantly with 2–6 nM CXCL12 and reached a plateau
with P20 nM CXCL12. Correspondingly, the UMB-2 signal
decreased strongly with 2–6 nM CXCL12. Minimal UMB-2 signal
Fig. 1. CXCL14 does not affect CXCL12-induced CXCR4 phosphorylation. (A)
Schematic representation of the non-stimulated (left) and CXCL12-stimulated
(right) CXCR4 C terminus. CXCR4 phosphorylation at serines 346,347 and binding
sites for UMB-2 and anti-pS346,347 antibodies are shown. Note that UMB-2 does
not recognize the phosphorylated C terminus of activated CXCR4. (B) HEK293 cells
stably expressing HA-tagged CXCR4 were treated with the indicated nM CXCL12
concentrations; when indicated, the cells were pre-incubated with 100 nM CXCL14.
The blot was sequentially reacted with anti-pS346,347, UMB-2 and anti-HA
antibodies (anti-HA visualizes total HA-CXCR4 and serves as loading control). (C)
Dose–response curves showing the signal ratio of anti-pS346,347 and anti-HA as
percentage of 20 nM CXCL12 (averaged from 4 independent experiments). (D) Cells
were pre-treated with the indicated concentrations of CXCR4 antagonists AMD3100
and AMD3465 before stimulation with 100 nM CXCL12. The blot was sequentially
reacted with anti-pS346,347 and anti-HA antibodies.
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quantitative CXCR4 phosphorylation. CXCL14 had no obvious effect
on these dose–response proﬁles (Fig. 1B). We repeated the exper-
iment for anti-pS346,347/anti-HA with CXCL12 concentrations
ranging from 0.2 to 20 nM and calculated dose–response curves
(Fig. 1C). This showed that neither the maximum effect of CXCL12
nor the EC50 (CXCL12: 0.87 nM; CXCL12 + CXCL14: 0.63 nM) were
signiﬁcantly changed by CXCL14. In contrast, 10 min pre-incuba-
tion with 5 lM AMD3100 or 0.2 lM AMD3465 abolished
CXCL12-induced S346/347 phosphorylation almost completely
(Fig. 1D). These experiments indicate that CXCL12-induced forma-
tion and GRK recognition of the CXCR4 active conformation are not
inﬂuenced by CXCL14.
3.2. CXCL14 does not inﬂuence G protein coupling of CXCR4
Next, we monitored the inﬂuence of CXCL14 on CXCL12-
induced CXCR4/G protein interaction by measuring calcium mobi-
lization in a FLIPR assay. In the 1st set of experiments, we directly
compared CXCL14 and CXCL12 effects in a double stimulation set-
ting (Fig. 2A). The ﬁrst stimulation was carried out after 30 s base-
line recording by adding assay buffer (solid lines) or 100 nM
CXCL14 (broken lines). CXCL14 evoked only a subtle response that
was similar to the response after assay buffer, indicating that
CXCL14 did not activate the Ca2+-pathway under these experimen-
tal conditions. The 2nd stimulation was carried out 90 s after the
ﬁrst stimulation using increasing concentrations of CXCL12
(Fig. 2A). In cells that received assay buffer in the ﬁrst stimulation,
CXCL12 caused a dose-dependent effect. The calculated EC50 for
buffer + CXCL12 was 17 nM (Fig. 2A0). CXCL14 pre-stimulation
affected neither the maximum effect nor the EC50 of the
CXCL12-induced response (EC50 for CXCL14 + CXCL12 was
14 nM; Fig. 2A0). In the 2nd set of experiments, cells were pre-trea-
ted for 15 min with vehicle, 100 nM CXCL14 or 6 lM AMD3100
before CXCL12 stimulation. AMD3100 caused a marked inhibition
of the CXCL12-induced response (Fig. 2B). The inhibitory effect of
the antagonist was calculated at 8 nM CXCL12 and amounted to
64% (Fig. 2B0). In contrast to AMD3100, CXCL14 did not modulate
CXCL12-induced calcium mobilization (Fig. 2B and B0). Thus, the
interaction of CXCL12-activated CXCR4 and G protein is not inﬂu-
enced by CXCL14.
3.3. CXCL14 does not inﬂuence MAPK signaling of CXCR4
Because CXCR4 activation is known to activate the Erk1,2 path-
way in HEK293 cells [28], we examined if CXCL14 inﬂuences the
kinetic of CXCL12-induced Erk1,2 phosphorylation. While 50 nM
CXCL12 induced robust Erk1,2 phosphorylation, 100 nM CXCL14
had only a subtle effect – if any (Fig. 3A and A0). Erk1,2 phosphor-
ylation after CXCL14/CXCL12 co-stimulation and CXCL12 stimula-
tion was indistinguishable (Fig. 3A and A0). Next, we pre-treated
the cells for 15 min with 6 lM AMD3100, 100 nM CXCL14 or vehi-
cle before adding 50 nM CXCL12 and found that AMD3100 pre-
treatment strongly reduced CXCL12-induced Erk1,2 phosphoryla-
tion whereas pre-treatment with CXCL14 had virtually no effect
on the CXCL12-induced response (Fig. 3B).
3.4. CXCL14 does not inﬂuence CXCL12-induced dynamic mass
redistribution (DMR)
Traditional examination of receptor-mediated signaling events
rely on measurements of individual second messengers like cAMP,
Ca2+ or inositol phosphates. To study the integrated cellular
response to CXCL12 in living cells, we applied label-free measure-
ments of DMR (Fig. 4). In this technology, polarized light is passed
Fig. 2. CXCL14 does not affect CXCL12-induced G protein coupling. G protein-dependent increase in cytosolic Ca2+ ([Ca2+]i) was monitored using FLIPR technology. (A, A0)
Cells were stimulated with 100 nM CXCL14 or assay buffer after 30 s baseline recording and – 90 s after the ﬁrst stimulus – with the indicated CXCL12 concentrations. (A)
Representative traces of a single experiment after normalization to the maximum response observed with 240 nM CXCL12 after buffer. (A0) Dose–response curves and EC50
values were calculated from 3 independent experiments with 2–4 repeats each. (B) Cells were pre-incubated for 15 min with assay buffer, 6 lM AMD3100 or 100 nM CXCL14
and then stimulated with the indicated CXCL12 concentrations. CXCL12 vs. AMD3100: ⁄⁄P < 0.01; ANOVA. (B0) The maximum response to 8 nM CXCL12 is signiﬁcantly
reduced by 6 lM AMD3100 but not by 100 nM CXCL14. ⁄⁄P < 0.01; ANOVA and Bonferroni’s post test.
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shifts of reﬂected light, which are caused by the redistribution of
cellular constituents, are recorded (Fig. 4A–D). Dose–response pro-
ﬁles were calculated after 300 s (Fig. 4E). This showed that CXCL14
induced DMR only at very high concentrations (P480 nM, Fig. 4A
and E). CXCL12 evoked a clear dose-dependent effect (EC50 of
CXCL12; 73 nM, Fig. 4B and E). Pre-treatment with 100 nM
AMD3465 (Fig. 4D and E) or 6 lM AMD3100 (not shown) had pro-
found antagonistic effects on CXCL12-induced DMR (reduction of
the response to 120 nM CXCL12 after 300 s: AMD3465, 78%,
P < 0.05; AMD3100, 54%, P = 0.05). In contrast, pre-treatment with
100 nM CXCL14 did not affect the CXCL12 dose–response proﬁle
(EC50 of CXCL12 + CXCL14; 88 nM, Fig. 4C and E).
3.5. CXCL14 does not inﬂuence CXCL12-induced CXCR4 internalization
It is well established that CXCL12 activation of CXCR4 leads to
receptor endocytosis [31]. Given the key role of this process in reg-
ulating the amount of receptor that is available for signaling at the
plasma membrane, we tested if CXCL14 inﬂuences CXCL12-
induced CXCR4 internalization. To allow monitoring the cell sur-
face level of CXCR4, an HA tag was attached to the receptor’s N ter-
minus. Cells were treated for 60 min with vehicle, 50 nM CXCL12,
100 nM CXCL14 or both chemokines. Confocal microscopy revealed
clear CXCR4 internalization in CXCL12- and CXCL12/CXCL14-trea-
ted cells but not in vehicle (CTRL)- or CXCL14-treated cells
(Fig. 5A–D). For quantitative analysis, an ELISA was performed
(Fig. 5E). Cell surface levels of HA-CXCR4 were determined 15, 30
and 60 min after stimulation in ﬁxed non-permeabilized cells.CXCL12-induced endocytosis of HA-CXCR4 was efﬁciently blocked
by 6 lM AMD3100 but not affected by 100 nM CXCL14. Levels of
HA-CXCR4 at the cell surface were similar in vehicle-treated and
CXCL14-treated cells at all time-points.
3.6. CXCL14 does not inﬂuence CXCL12-induced CXCR4
phosphorylation and DMR in Jurkat T cells
Because our experiments with HA-CXCR4-transfected HEK293
cells did not show any effects of CXCL14 on the CXCL12/CXCR4
pathway, we wished to test if CXCL14 inﬂuences CXCL12-induced
CXCR4 activation and signaling in a cell line for which CXCL14
effects on CXCL12/CXCR4-mediated chemotaxis have been
reported [13]. We chose Jurkat T cells because these cells express
high levels of endogenous CXCR4. We determined dose–response
proﬁles of CXCL12-induced CXCR4 phosphorylation and DMR in
the absence and in the presence of 100 nM CXCL14 (Fig. 6). CXCL12
dose-dependent CXCR4 phosphorylation (as reﬂected by loss of
UMB-2 binding) and DMR were readily observed with Jurkat cells.
Both responses were not inhibited by CXCL14. EC50 values of
53 nM and 48 nM were calculated for DMR induced by CXCL12
and CXCL12 + CXCL14, respectively.
3.7. Summary and conclusions
Using human leukemia-derived cell lines and CD34+ progenitor
cells, Tanegashima and colleagues reported (1) that CXCL14 binds
to CXCR4 with high afﬁnity and inhibits CXCL12-induced migra-
tion, (2) that CXCL12 does not interfere with the CXCL14/CXCR4
Fig. 3. CXCL14 does not affect CXCL12-induced MAPK phosphorylation. CXCL12-
induced phosphorylation of Erk1,2 was examined in immunoblots. (A) Vehicle
(0 min), 50 nM CXCL12, 100 nM CXCL14 or 50 nM CXCL12 + 100 nM CXCL14 were
added to stably CXCR4-tranfected HEK293 cells for the indicated time before cells
were harvested. Immunoblots were reacted simultaneously with antibodies for
pErk1,2 and total Akt as loading control. (A0) The pErk1,2/Akt ratio was calculated
from 3 independent experiments with 2–3 cultures each. (B) Cells in groups 4 and 5
were pre-treated for 15 min with 100 nM CXCL14 and 6 lMAMD3100, respectively.
For stimulation, 100 nM CXCL14 (group 2) or 50 nM CXCL12 (3–5) were used. The
pErk1,2/Akt ratio was determined in a single experiment with 2–3 cultures per
group. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001; ANOVA and Bonferroni’s post test.
Fig. 4. CXCL14 does not affect CXCL12-induced dynamic mass redistribution. (A–D) Rep
different CXCL14 and CXCL12 concentrations. Cells in (C and D) were pre-treated for 1
calculated from 3 repeats. (E) Dose–response proﬁles after 300 s (calculated from 2 to 3
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These results are best reconciled by direct (allosteric) CXCL14-
mediated inhibition of the CXCL12/CXCR4 pathway. As CXCL12
has long been considered the only endogenous chemokine ligand
of CXCR4, we tested this hypothesis with a different cell line and
different approaches than Tanegashima and colleagues. Using
CXCR4-transfected HEK293 cells, we did not observe signiﬁcant
CXCL14-induced signaling events in calcium mobilization, DMR
and MAPK assays. This indicates that these cells do not express
receptors that would enable CXCL14 to activate downstream path-
ways. In contrast, CXCL12 evoked clear dose- and time-dependent
responses through CXCR4. Importantly, CXCL14 had no inﬂuence
on CXCL12-induced CXCR4 phosphorylation at serines 346/347, G
protein coupling, Erk1,2 phosphorylation and DMR. CXCL14 did
also not internalize CXCR4 when applied alone and did not affect
CXCL12-induced CXCR4 internalization, suggesting that the
reported CXCL14/CXCR4 interaction [13,14] does not regulate the
amount of CXCR4 that is available for signaling at the cell surface.
Also in Jurkat T cells, where CXCL14 was reported to inhibit
CXCL12-induced chemotaxis [13], CXCL14 did not affect CXCL12-
induced CXCR4 phosphorylation and CXCL12-induced DMR. Thus,
neither in Jurkat T cells expressing endogenous CXCR4 nor in
HEK293 cells expressing recombinant CXCR4 were we able to dem-
onstrate CXCL14 effects that would be consistent with direct (allo-
steric) modulation of CXCL12/CXCR4 signaling. Whether or not
there was a high afﬁnity interaction between CXCL14 and CXCR4
under our experimental conditions was beyond the scope of our
analyses. Still, we purchased CXCL14 from the same source as
Tanegashima et al. [14]. We thus conclude that CXCL12 should still
be considered the only bona ﬁde chemokine ligand of CXCR4. Func-
tional interaction of CXCL12 and CXCL14 pathways are possible
[13,14,20] but might require a yet to be identiﬁed CXCL14 receptor.
The interaction might occur at the receptor level through heterodi-
merization of CXCR4 with the putative CXCL14 receptor or down-
stream of these receptors.resentative time-dependent responses of stably CXCR4-transfected HEK293 cells to
0 min with 100 nM CXCL14 (C) or 100 nM AMD3465 (D). Data are mean + S.E.M.
independent experiments with 3 repeats each).
Fig. 5. CXCL14 does not affect CXCL12-induced CXCR4 internalization. (A–D) Confocal images of HA-CXCR4 in stably transfected HEK293 cells. Cells were stimulated for
60 min with vehicle (CTRL), 50 nM CXCL12, 100 nM CXCL14 or 50 nM CXCL12 + 100 nM CXCL14. Recombinant CXCR4 was visualized with anti-HA and ﬂuorophore-coupled
secondary antibody. Scale bar = 20 lm. (E) Cell surface levels of HA-CXCR4 were quantiﬁed using ELISA. The CXCR4 signal was normalized to vehicle-treated cells at each
time-point. Data are mean + S.E.M. calculated from 3 independent experiments with 6 repeats each. ⁄⁄,##P < 0.01, ⁄⁄⁄,###P < 0.001, ANOVA and Bonferroni’s post-test (⁄CXCL12
vs. vehicle; #CXCL12 vs. CXCL12 + AMD3100).
Fig. 6. CXCL14 does not affect CXCL12-induced CXCR4 phosphorylation and DMR in Jurkat T cells. (A) Jurkat T cells were pre-incubated with 100 nM CXCL14 or vehicle and
then stimulated for 10 min with the indicated nM CXCL12 concentrations. The blot was simultaneously reacted with UMB-2 and anti-transferrin receptor (TFR) antibodies
(TFR serves as loading control). CXCL12-induced CXCR4 phosphorylation is reﬂected by loss of UMB-2 signal. (B) The signal ratio of UMB-2 and anti-HA was expressed as
percent of control cells receiving only vehicle (data are mean + S.E.M. from 4 independent experiments). ANOVA revealed no differences between CXCL12- and corresponding
CXCL14/CXCL12-stimulated groups. (C–E) Time-dependent responses of 200000 Jurkat T cells to different CXCL14 and CXCL12 concentrations. Cells in (E) were pre-treated
for 10 min with 100 nM CXCL14. Data are mean + S.E.M. (calculated from 4 repeats) and are representative for two independent experiments.
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